Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Top Cited Papers
- 1 September 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (9), 1239-1251
- https://doi.org/10.1016/s1470-2045(19)30388-2
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Meso Scale Diagnostics
- Roche
- Merck Sharp and Dohme
- Les Laboratories Pierre Fabre
- British Microcirculation Society
- Amgen
This publication has 19 references indexed in Scilit:
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJournal of Clinical Oncology, 2018
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanomaEuropean Journal Of Cancer, 2017
- Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnosticAnnals of Oncology, 2017
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJama-Journal Of The American Medical Association, 2016
- PD-1 Blockade Expands Intratumoral Memory T CellsCancer Immunology Research, 2016
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In VivoThe Journal of Immunology, 2015
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009